[Significance and effect of Glucosidorum Tripterygii tororum on expressions of Foxp3 in regulatory T cells in type 1 diabetic rat model].
OBJECTIVE
To investigate the significance and effect of Glucosidorum Tripterygii tororum (GTT) on the expressions of Foxp3 in CD4(+)CD25(+) regulatory T cells (Tr) in type 1 diabetic rat model.


METHODS
48 rats were divided evenly into 3 groups by random. Diabetic model was developed by multiple low dose intraperitoneal injection of streptozotocin in group II, III, and group I was treated as normal control. After the establishment of the model, administration of GTT was conducted in group III, which was performed once a day, lasting three monthes. Lymphocyte proliferation was detected by lymphocyte transformation test (MTT assay). The expression of Foxp3 mRNA was measured in peripheral blood and spleen by using real-time PCR. The expression of Foxp3 protein in lymphoid node and spleen was detected by immunohistochemistry.


RESULTS
The blood glucose level in group II, III was obviously higher than that of control group (P<0.01), followed with lymphocyte infiltrating in pancreatic islets. The infiltrating degree in group III was decreased than that of group II. The proliferation of splenic lymphocyte in group II, III was evidently increased comparing with the control group (P<0.01). After administration of GTT, the proliferation in group III was lower than that in group II. In group II, III, the expressions of Foxp3 mRNA and protein increased markedly compared with control group (P<0.05). Moreover, the level in group III was especially enhanced, but compared with group II, there was no significantly difference (P>0.05).


CONCLUSIONS
Foxp3(+) Tr may involve in the pathogenesy of type 1 diabetes indused by STZ. GTT did have therapeutical effect on type 1 diabetes, possibly through upregulating the expressions of Foxp3 in Tr.
Liang
Chun-lian
CL
Department of Immunology, Qingdao University Medical College, Qingdao 266021, China. liangchunlian1@sina.com
Wang
Jing
J
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D051858:Forkhead Transcription Factors / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007150:Immunohistochemistry; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D008297:Male; D016133:Polymerase Chain Reaction; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000378:metabolism
D004365:Drugs, Chinese Herbal; D051858:Forkhead Transcription Factors; C500522:Foxp3 protein, rat; D007004:Hypoglycemic Agents; D053645:Interleukin-2 Receptor alpha Subunit